$14.140
-0.464 (-3.28%)收盤時
IOVA 資訊
IOVA 事件
Iovance's Lifileucel with Pembrolizumab Shows 62.5% Objective Response Rate in Melanoma
Iovance announced that one-time lifileucel combined with pembrolizumab demonstrated a 62.5% objective response rate and a 29.2% complete response rate, with median overall survival not reached at 50.9 months of median study follow-up in the final Phase 2 analysis in frontline advanced melanoma. The final analysis in frontline advanced melanoma included 24 patients treated with one-time lifileucel that met pre-determined manufacturing specifications and pembrolizumab monotherapy for up to 24 months. Median progression-free survival was 19.8 months. Median PFS after second line of therapy was 34.3 months, "indicating that subsequent systemic therapy remains feasible after frontline lifileucel and pembrolizumab, including additional ICI therapy," the company added.
Iovance Shares Drop 3% to $13.67 After New Melanoma Data
Iovance drops 3% to $13.67 after new melanoma data
Iovance Biotherapeutics Appoints Noah Berkowitz as Chief Medical Officer
Iovance Biotherapeutics (IOVA) announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, CMO, effective September 30, 2026. Berkowitz previously served as Senior Vice President and Therapeutic Area Head, Hematology at Bristol Myers Squibb (BMY)
Major Averages Decline as 30-Year Bond Yield Hits Highest Level Since 2002
The major averages edged downward as borrowing costs continued to climb. The 30-year bond yield hit the highest level since 2002 and while some of stock weakness is being mitigated by a dip in oil prices, the commodity continues to trade at elevated levels with tensions between the U.S. and Iran unresolved.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:OpenAI has scrapped the launch of its upcoming GPT-6.1 model amid security concerns, WSJ reportsMetaannounced Muse for Small BusinessOura said it is postponing its IPO due to "uncertainty" in the IPO marketCarMaxreported upbeat Q2 earnings and revenue and said it plans to resume share repurchases in Q3Carnivalreported better-than-expected Q3 results and provided upbeat FY26 guidance2. WALL STREET CALLS:Deutsche Bank upgraded Netflix, sees attractive entry point after selloffPepsiCowas downgraded for a second straight day, with JPMorgan citing a stalled U.S. turnaroundMizuho upgraded Stitch Fixto Neutral with short case played outMonday.comdowngraded to Neutral at JPMorganGoosehead Insuranceupgraded to Buy at Texas Capital after Muse-driven selloff3. AROUND THE WEB:OpenAI is targeting $30B in new funds at a $1.4T valuation, Bloomberg reportsKalshi is in talks with Tiger Global and Dragoneer to raise $1B in funding, Reuters reportsDisneyis laying off several hundred staff across multiple departments, Variety saysAI research leaders at OpenAI, Anthropic, Microsoft, and Metaare calling for oversight into automated AI research, WSJ reportsAnthropic plans to spend $518B on cloud/infrastructure obligations, Reuters says4. MOVERS:Iovance Biotherapeuticsgained after raising its outlook for FY26Perella Weinbergincreased after the Wall Street Journal reported that Piper Sandleris in talks to acquire the companyOraclewas higher after announcing a new storage service for cloud with NetAppuniQurefell in New York after announcing additional data from its studies of ifezuntirgene inilparvovecXeriswas lower after Bloomberg reported that Lundbeck has expressed interest in acquiring Xeris5. EARNINGS/GUIDANCE:AAR Corp.reported Q1 results and provided guidance for Q2 and FY27IDT Corp.reported Q4 results, with EPS higher year-over-yearBWX Technologiesprovided guidance for FY26 and FY30SmartStop Self Storageraised its outlook for FY26Jefferies Financialreported Q3 results, with EPS and revenue beating consensusINDEXES:The Dow fell 131.59, or 0.26%, to 51,349.92, the Nasdaq lost 22.84, or 0.09%, to 26,797.54, and the S&P 500 declined 12.85, or 0.17%, to 7,670.84.
Iovance Biotherapeutics Stock Rises 27.8% to $14.05
Iovance Biotherapeutics is up 27.8%, or $3.06 to $14.05.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。